Kindai University

Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials

Retrieved on: 
Monday, March 20, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, Kindai University, Society, Central nervous system, Febrile neutropenia, PRS, HER3, Associate professor, Safety, DOR, DCR, Trastuzumab deruxtecan, Survival, European Society for Medical Oncology, Outer ring road, ILD, TKI, Breast, NSCLC, History, Lung cancer, Lung, Doctor of Philosophy, CNS, PFS, ORR, Fatigue, Death, MD, Patient, EGFR, DXD, Hypokalemia, Anemia, Cancer, Annual general meeting, Nausea, Periodic breathing, ADC, SD, TSE, Breast cancer, Medical imaging, Pharmaceutical industry, Nursing

Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s proprietary DXd ADC technology.

Key Points: 
  • Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s proprietary DXd ADC technology.
  • Responses with patritumab deruxtecan were seen in patients across a broad range of HER3 expression and across multiple mechanisms of EGFR TKI resistance.
  • Safety of patritumab deruxtecan seen in this phase 1 trial was consistent with that previously observed in patients with EGFR-mutated NSCLC.
  • As of the data cut-off on January 28, 2022, eight patients remained on study treatment with patritumab deruxtecan.

ANNUAL BERGGRUEN PRIZE FOR PHILOSOPHY & CULTURE AWARDED TO JAPANESE PHILOSOPHER KOJIN KARATANI

Retrieved on: 
Thursday, December 8, 2022
Kojin Karatani, Origin, Democracy, LOS, Exercise, Linguistics, Vocabulary, Yale University, Society, Kindai University, Animal rights, Repetition, Government, History, Berggruen Institute, Anger, Paganini Competition, Immanuel Kant, Berggruen, University of California, Los Angeles, Civilization, Humanities, University, Movement, Fukushima Daiichi nuclear disaster, Poverty, Public health, Noema, University of Tokyo, Essay, Metaphor, Structure, BBC, Berggruen Prize, Thought, Prize, Fear, Capitalism, Altruism, Literature, Social, Columbia University, Education, Hosei University, Research, Economics, BBC World Service, Gunzo, Management, Language, Philosophy, Architecture

TOKYO and LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- Today, the Berggruen Prize Jury announced its selection of preeminent Japanese philosopher and literary critic Kojin Karatani as the winner of the 2022 Berggruen Prize for Philosophy & Culture. The $1 million award is given annually to thinkers whose ideas have profoundly shaped human self-understanding and advancement in a rapidly changing world. Karatani is the first Asian laureate of the Berggruen Philosophy & Culture Prize, a rare thinker whose ideas move across philosophy, literary theory, aesthetics, linguistics, economics, and politics—East and West; past and present. The Berggruen Prize Jury has selected Kojin Karatani for his "radically original contributions to modern philosophy, the history of philosophy, and political thinking—making Karatani's work particularly valuable in the current era of troubled global capitalism, crisis in democratic states, and resurgent but seldom self-critical nationalism."

Key Points: 
  • TOKYO and LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- Today, the Berggruen Prize Jury announced its selection of preeminent Japanese philosopher and literary critic Kojin Karatani as the winner of the 2022 Berggruen Prize for Philosophy & Culture.
  • Karatani is the first Asian laureate of the Berggruen Philosophy & Culture Prize, a rare thinker whose ideas move across philosophy, literary theory, aesthetics, linguistics, economics, and politicsEast and West; past and present.
  • Not an arm-chair philosopher, Kojin Karatani has actively promoted a modern form of the kind of reciprocity he saw in ancient Ionian culture, which he calls 'associationism,'" said Berggruen Institute Chairman Nicolas Berggruen.
  • Karatani will receive the Berggruen Prize for Philosophy & Culture in Spring 2023 in a celebration to be held in Tokyo, Japan.

ANNUAL BERGGRUEN PRIZE FOR PHILOSOPHY & CULTURE AWARDED TO JAPANESE PHILOSOPHER KOJIN KARATANI

Retrieved on: 
Thursday, December 8, 2022
Kojin Karatani, Origin, Democracy, LOS, Exercise, Linguistics, Vocabulary, Yale University, Society, Powers, Kindai University, Animal rights, Repetition, Government, History, Berggruen Institute, Anger, Paganini Competition, Immanuel Kant, Berggruen, University of California, Los Angeles, Civilization, Humanities, University, Movement, Fukushima Daiichi nuclear disaster, Poverty, Public health, Noema, University of Tokyo, Essay, Metaphor, Structure, BBC, Berggruen Prize, Thought, Prize, Fear, Capitalism, Altruism, Literature, Social, Columbia University, Education, Hosei University, Research, Economics, BBC World Service, Gunzo, Management, Language, Philosophy, Architecture

TOKYO and LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- Today, the Berggruen Prize Jury announced its selection of preeminent Japanese philosopher and literary critic Kojin Karatani as the winner of the 2022 Berggruen Prize for Philosophy & Culture. The $1 million award is given annually to thinkers whose ideas have profoundly shaped human self-understanding and advancement in a rapidly changing world. Karatani is the first Asian laureate of the Berggruen Philosophy & Culture Prize, a rare thinker whose ideas move across philosophy, literary theory, aesthetics, linguistics, economics, and politics—East and West; past and present. The Berggruen Prize Jury has selected Kojin Karatani for his "radically original contributions to modern philosophy, the history of philosophy, and political thinking—making Karatani's work particularly valuable in the current era of troubled global capitalism, crisis in democratic states, and resurgent but seldom self-critical nationalism."

Key Points: 
  • TOKYO and LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- Today, the Berggruen Prize Jury announced its selection of preeminent Japanese philosopher and literary critic Kojin Karatani as the winner of the 2022 Berggruen Prize for Philosophy & Culture.
  • Karatani is the first Asian laureate of the Berggruen Philosophy & Culture Prize, a rare thinker whose ideas move across philosophy, literary theory, aesthetics, linguistics, economics, and politicsEast and West; past and present.
  • Not an arm-chair philosopher, Kojin Karatani has actively promoted a modern form of the kind of reciprocity he saw in ancient Ionian culture, which he calls 'associationism,'" said Berggruen Institute Chairman Nicolas Berggruen.
  • Karatani will receive the Berggruen Prize for Philosophy & Culture in Spring 2023 at a celebration to be held in Tokyo, Japan.

HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial

Retrieved on: 
Thursday, October 14, 2021
Death, CT, Technology, Degenerative disease, Diagnosis, Plaque, Silicon, Acute coronary syndrome, Heart, CCTA, 3D, Mount Sinai Hospital, Man, Rupture, Computational fluid dynamics, Multicenter Automatic Defibrillator Implantation Trial, MSA, Physician, IVUS, FACC, Algorithm, Woman, Interventional cardiology, Coronary artery disease, Intelligence, Trial of the century, Physiology, Patient, CAD, GLOBE, Muscle tissue, Anatomy, Kindai University, Moyamoya disease, Safety, CTA, DO, Principal, Deep learning, Cone Health, Mechanism, Analyse, Medical imaging

It is clear, however, that coronary plaque is the driving force behind understanding a patients risk of having a heart attack, said Dr. Meckel, lead Principal Investigator for REVEALPLAQUE at Bryan Heart.

Key Points: 
  • It is clear, however, that coronary plaque is the driving force behind understanding a patients risk of having a heart attack, said Dr. Meckel, lead Principal Investigator for REVEALPLAQUE at Bryan Heart.
  • To be able to accurately and non-invasively understand a patients plaque burden would be game changing in physicians abilities to save a patients life from a heart attack.
  • The REVEALPLAQUE trial is planned to enroll 250 patients with stable coronary artery disease from approximately 15 sites across the U.S. and Japan.
  • The HeartFlow FFRct Analysis is commercially available in the United States, UK, Canada, Europe and Japan.